Errata


In the article by Westhovens et al published in the April 2006 issue of Arthritis & Rheumatism (pp. 1075–1086), there were several errors under the Dose Escalation heading in the Results section. The two paragraphs under that heading should have read as follows (corrections in italics):

Of the 329 patients who entered the dose-escalation phase of the study, 100 patients (30.4%) received a dose escalation because they did not meet the criteria for response at week 22 or because they initially met the response criteria at week 22 but later met the criteria for a disease flare. Fifty-nine patients (17.9%) received 1 dose increase for a total of 4.5 mg/kg, 21 patients (6.4%) received 2 increases for a total dose of 6.0 mg/kg, 13 patients (4.0%) received 3 increases for a total of 7.5 mg/kg, 7 patients (2.1%) received 4 increases for a total dose of 9 mg/kg, the latter being the maximum allowed by the study protocol. Nine additional patients received dose escalation in error; i.e., they did not meet the criteria for lack of response or flare.

Improved efficacy was observed in the patients in group 2 who received dose escalations (13). Nevertheless, patients in group 2 who continued to receive 3 mg/kg infliximab in combination with MTX had similar frequencies of infections, serious infections, or other adverse events compared with those who received dose escalations. Of the 109 patients in group 2 who received a dose escalation, 77 (71%) reported experiencing an adverse event, 14 (13%) reported experiencing a serious adverse event, 39 (36%) reported developing an infection, and 2 (2%) reported developing a serious infection between weeks 22 and 54. Of the 220 patients in group 2 who did not receive a dose escalation at any time, 160 (73%) reported experiencing an adverse event, 19 (9%) reported experiencing a serious adverse event, 80 (36%) reported developing an infection, and 5 (2%) reported developing a serious infection between baseline and week 54. The mean duration of treatment was 30.6 weeks for patients with a dose escalation and 31.0 weeks for patients without a dose escalation.

The changes do not affect the overall conclusions of the study.

We regret the errors.

Ancillary